Do analysts recommend TVRD or ENVB?

Tvardi Therapeutics presently has a consensus target price of $18.00, suggesting a potential upside of 922.73%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tvardi Therapeutics is more favorable than Enveric Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tvardi Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, TVRD or ENVB?

Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tvardi Therapeutics N/A N/A -$18.21M -$2.79 N/A Enveric Biosciences N/A N/A -$8.77M -$12.65 N/A

Is TVRD or ENVB more profitable?

Tvardi Therapeutics' return on equity of -145.40% beat Enveric Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -145.40% -91.11% Enveric Biosciences N/A -168.04% -145.95%

Does the media prefer TVRD or ENVB?

In the previous week, Tvardi Therapeutics had 3 more articles in the media than Enveric Biosciences. MarketBeat recorded 5 mentions for Tvardi Therapeutics and 2 mentions for Enveric Biosciences. Enveric Biosciences' average media sentiment score of 1.89 beat Tvardi Therapeutics' score of 0.97 indicating that Enveric Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tvardi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enveric Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer ENVB or TXMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate ENVB or COCP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ENVB or COCP more profitable?

Enveric Biosciences' return on equity of -168.04% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Enveric Biosciences N/A -168.04% -145.95% Cocrystal Pharma N/A -207.47% -123.33%

Does the media prefer ENVB or COCP?

In the previous week, Enveric Biosciences and Enveric Biosciences both had 2 articles in the media. Enveric Biosciences' average media sentiment score of 1.89 beat Cocrystal Pharma's score of 0.94 indicating that Enveric Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enveric Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cocrystal Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BFRI or ENVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor BFRI or ENVB?

In the previous week, Biofrontera had 4 more articles in the media than Enveric Biosciences. MarketBeat recorded 6 mentions for Biofrontera and 2 mentions for Enveric Biosciences. Enveric Biosciences' average media sentiment score of 1.89 beat Biofrontera's score of 0.70 indicating that Enveric Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biofrontera 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enveric Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer EGRX or ENVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is EGRX or ENVB more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat Enveric Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Eagle Pharmaceuticals N/A N/A N/A Enveric Biosciences N/A -168.04% -145.95%

Does the media favor EGRX or ENVB?

In the previous week, Enveric Biosciences had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 2 mentions for Enveric Biosciences and 1 mentions for Eagle Pharmaceuticals. Enveric Biosciences' average media sentiment score of 1.89 beat Eagle Pharmaceuticals' score of 0.75 indicating that Enveric Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eagle Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enveric Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Enveric Biosciences (ENVB) Competitors

$1.46 -0.02 (-1.35%)

Closing price 04:00 PM Eastern

Extended Trading

$1.46 +0.01 (+0.34%)

As of 04:18 PM Eastern

Compare

ENVB vs. TVRD, TXMD, COCP, BFRI, and EGRX

Should you buy Enveric Biosciences stock or one of its competitors? Enveric Biosciences's main competitors and comparable companies include Tvardi Therapeutics (TVRD), TherapeuticsMD (TXMD), Cocrystal Pharma (COCP), Biofrontera (BFRI), and Eagle Pharmaceuticals (EGRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Enveric Biosciences compare to Tvardi Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

In the previous week, Tvardi Therapeutics had 3 more articles in the media than Enveric Biosciences. MarketBeat recorded 5 mentions for Tvardi Therapeutics and 2 mentions for Enveric Biosciences. Enveric Biosciences' average media sentiment score of 1.89 beat Tvardi Therapeutics' score of 0.97 indicating that Enveric Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tvardi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enveric Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Tvardi Therapeutics' return on equity of -145.40% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-145.40%	-91.11%
Enveric Biosciences	N/A	-168.04%	-145.95%

Tvardi Therapeutics presently has a consensus target price of $18.00, suggesting a potential upside of 922.73%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tvardi Therapeutics is more favorable than Enveric Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	N/A	N/A	-$18.21M	-$2.79	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$12.65	N/A

44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by company insiders. Comparatively, 2.4% of Enveric Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Tvardi Therapeutics has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

Summary

Tvardi Therapeutics beats Enveric Biosciences on 10 of the 14 factors compared between the two stocks.

How does Enveric Biosciences compare to TherapeuticsMD?

Enveric Biosciences (NASDAQ:ENVB) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 2.4% of Enveric Biosciences shares are owned by insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Enveric Biosciences has a net margin of 0.00% compared to TherapeuticsMD's net margin of -6.64%. TherapeuticsMD's return on equity of -1.09% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-168.04%	-145.95%
TherapeuticsMD	-6.64%	-1.09%	-0.78%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Enveric Biosciences had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 2 mentions for Enveric Biosciences and 1 mentions for TherapeuticsMD. Enveric Biosciences' average media sentiment score of 1.89 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
Enveric Biosciences	Very Positive
TherapeuticsMD	Very Positive

Enveric Biosciences has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

TherapeuticsMD has higher revenue and earnings than Enveric Biosciences. Enveric Biosciences is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$8.77M	-$12.65	N/A
TherapeuticsMD	$3.02M	8.28	-$570K	$0.02	108.00

Summary

TherapeuticsMD beats Enveric Biosciences on 7 of the 11 factors compared between the two stocks.

How does Enveric Biosciences compare to Cocrystal Pharma?

Enveric Biosciences (NASDAQ:ENVB) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Enveric Biosciences and Enveric Biosciences both had 2 articles in the media. Enveric Biosciences' average media sentiment score of 1.89 beat Cocrystal Pharma's score of 0.94 indicating that Enveric Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enveric Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cocrystal Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enveric Biosciences has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market.

13.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 2.4% of Enveric Biosciences shares are held by insiders. Comparatively, 39.4% of Cocrystal Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Enveric Biosciences' return on equity of -168.04% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-168.04%	-145.95%
Cocrystal Pharma	N/A	-207.47%	-123.33%

Enveric Biosciences has higher earnings, but lower revenue than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$8.77M	-$12.65	N/A
Cocrystal Pharma	$330K	66.54	-$8.83M	-$0.76	N/A

Summary

Enveric Biosciences and Cocrystal Pharma tied by winning 5 of the 10 factors compared between the two stocks.

How does Enveric Biosciences compare to Biofrontera?

Biofrontera (NASDAQ:BFRI) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are owned by institutional investors. 8.1% of Biofrontera shares are owned by company insiders. Comparatively, 2.4% of Enveric Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Biofrontera had 4 more articles in the media than Enveric Biosciences. MarketBeat recorded 6 mentions for Biofrontera and 2 mentions for Enveric Biosciences. Enveric Biosciences' average media sentiment score of 1.89 beat Biofrontera's score of 0.70 indicating that Enveric Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biofrontera	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enveric Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Biofrontera has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

Enveric Biosciences has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Biofrontera's return on equity of -145.81% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-13.78%	-145.81%	-31.30%
Enveric Biosciences	N/A	-168.04%	-145.95%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Enveric Biosciences has lower revenue, but higher earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$46.18M	0.38	-$10.54M	-$0.45	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$12.65	N/A

Summary

Biofrontera beats Enveric Biosciences on 8 of the 14 factors compared between the two stocks.

How does Enveric Biosciences compare to Eagle Pharmaceuticals?

Eagle Pharmaceuticals (NASDAQ:EGRX) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 2.4% of Enveric Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Eagle Pharmaceuticals' return on equity of 0.00% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
Enveric Biosciences	N/A	-168.04%	-145.95%

In the previous week, Enveric Biosciences had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 2 mentions for Enveric Biosciences and 1 mentions for Eagle Pharmaceuticals. Enveric Biosciences' average media sentiment score of 1.89 beat Eagle Pharmaceuticals' score of 0.75 indicating that Enveric Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eagle Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enveric Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Eagle Pharmaceuticals has higher revenue and earnings than Enveric Biosciences. Enveric Biosciences is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.06	$35.64M	$1.18	1.09
Enveric Biosciences	N/A	N/A	-$8.77M	-$12.65	N/A

Eagle Pharmaceuticals has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

Summary

Eagle Pharmaceuticals beats Enveric Biosciences on 8 of the 12 factors compared between the two stocks.

Get Enveric Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENVB vs. The Competition

Export

Metric	Enveric Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.54M	$12.44B	$7.16B	$14.34B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	-0.12	792.10	273.41	25.32
Price / Sales	N/A	763.25	674.51	98.42
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	0.21	10.40	10.38	6.20
Net Income	-$8.77M	$2.83B	$3.49B	$358.18M
7 Day Performance	2.82%	-3.28%	-2.17%	-1.58%
1 Month Performance	-4.89%	0.80%	-0.37%	-3.60%
1 Year Performance	-87.06%	3.62%	19.18%	5.95%

Enveric Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENVB Enveric Biosciences	1.0204 of 5 stars	$1.46 -1.4%	N/A	-87.3%	$6.54M	N/A	N/A	20	News Coverage Positive News
TVRD Tvardi Therapeutics	3.694 of 5 stars	$1.91 -1.8%	$18.00 +844.4%	-94.6%	$25.42M	N/A	N/A	80	News Coverage Analyst Upgrade
TXMD TherapeuticsMD	1.5198 of 5 stars	$2.17 +1.4%	N/A	+94.6%	$25.11M	$3.02M	108.50	420	Positive News
COCP Cocrystal Pharma	0.8497 of 5 stars	$1.28 +8.1%	N/A	-25.9%	$24.56M	$330K	N/A	10	Gap Up
BFRI Biofrontera	1.0559 of 5 stars	$1.58 +1.0%	N/A	+61.7%	$23.39M	$46.18M	N/A	70	News Coverage Analyst Upgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENVB) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enveric Biosciences (ENVB) Competitors

ENVB vs. TVRD, TXMD, COCP, BFRI, and EGRX

How does Enveric Biosciences compare to Tvardi Therapeutics?

Summary

How does Enveric Biosciences compare to TherapeuticsMD?

Summary

How does Enveric Biosciences compare to Cocrystal Pharma?

Summary

How does Enveric Biosciences compare to Biofrontera?

Summary

How does Enveric Biosciences compare to Eagle Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENVB vs. The Competition

Enveric Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enveric Biosciences (ENVB) Competitors

ENVB vs. TVRD, TXMD, COCP, BFRI, and EGRX

How does Enveric Biosciences compare to Tvardi Therapeutics?

Does the media prefer TVRD or ENVB?

Is TVRD or ENVB more profitable?

Do analysts recommend TVRD or ENVB?

Which has stronger earnings and valuation, TVRD or ENVB?

Do insiders and institutionals hold more shares of TVRD or ENVB?

Which has more risk & volatility, TVRD or ENVB?

Summary

How does Enveric Biosciences compare to TherapeuticsMD?

Do institutionals & insiders have more ownership in ENVB or TXMD?

Is ENVB or TXMD more profitable?

Do analysts prefer ENVB or TXMD?

Does the media favor ENVB or TXMD?

Which has more volatility and risk, ENVB or TXMD?

Which has preferable earnings and valuation, ENVB or TXMD?

Summary

How does Enveric Biosciences compare to Cocrystal Pharma?

Do analysts rate ENVB or COCP?

Does the media prefer ENVB or COCP?

Which has more risk and volatility, ENVB or COCP?

Do insiders and institutionals have more ownership in ENVB or COCP?

Is ENVB or COCP more profitable?

Which has preferable valuation & earnings, ENVB or COCP?

Summary

How does Enveric Biosciences compare to Biofrontera?

Do institutionals and insiders believe in BFRI or ENVB?

Does the media favor BFRI or ENVB?

Which has more risk and volatility, BFRI or ENVB?

Is BFRI or ENVB more profitable?

Do analysts prefer BFRI or ENVB?

Which has higher valuation and earnings, BFRI or ENVB?

Summary

How does Enveric Biosciences compare to Eagle Pharmaceuticals?

Do analysts prefer EGRX or ENVB?

Do institutionals & insiders have more ownership in EGRX or ENVB?

Is EGRX or ENVB more profitable?

Does the media favor EGRX or ENVB?

Which has better earnings & valuation, EGRX or ENVB?

Which has more risk & volatility, EGRX or ENVB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENVB vs. The Competition

Enveric Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools